Jump to content

Diacylglycerol kinase

From Wikipedia, the free encyclopedia
(Redirected from Diacylglycerol Kinase)
Diacylglycerol kinase
DgkB, soluble DAGK from Staphylococcus aureus. α-helices in red, β-strands in yellow, coils in green.
Identifiers
EC no.2.7.1.107
CAS no.60382-71-0
Databases
IntEnzIntEnz view
BRENDABRENDA entry
ExPASyNiceZyme view
KEGGKEGG entry
MetaCycmetabolic pathway
PRIAMprofile
PDB structuresRCSB PDB PDBe PDBsum
Search
PMCarticles
PubMedarticles
NCBIproteins
Prokaryotic diacylglycerol kinase
Identifiers
SymbolDAGK_prokar
PfamPF01219
InterProIPR000829
PROSITEPDOC00820
OPM superfamily196
OPM protein4d2e
Available protein structures:
Pfam  structures / ECOD  
PDBRCSB PDB; PDBe; PDBj
PDBsumstructure summary
Diacylglycerol kinase catalytic domain
Identifiers
SymbolDAGK_cat
PfamPF00781
Pfam clanCL0240
InterProIPR001206
SMARTDAGKc
Available protein structures:
Pfam  structures / ECOD  
PDBRCSB PDB; PDBe; PDBj
PDBsumstructure summary
Diacylglycerol kinase accessory domain
Identifiers
SymbolDAGK_acc
PfamPF00609
InterProIPR000756
SMARTDAGKa
Available protein structures:
Pfam  structures / ECOD  
PDBRCSB PDB; PDBe; PDBj
PDBsumstructure summary

Diacylglycerol kinase (DGK or DAGK) is a family of enzymes that catalyzes the conversion of diacylglycerol (DAG) to phosphatidic acid (PA), utilizing ATP as a source of the phosphate.[1] In non-stimulated cells, DGK activity is low, allowing DAG to be used for glycerophospholipid biosynthesis, but on receptor activation of the phosphoinositide pathway, DGK activity increases, driving the conversion of DAG to PA. As both lipids are thought to function as bioactive lipid signaling molecules with distinct cellular targets, DGK therefore occupies an important position, effectively serving as a switch by terminating the signalling of one lipid while simultaneously activating signalling by another.[2]

In bacteria, DGK is very small (13 to 15 kDa) membrane protein which seems to contain three transmembrane domains.[3] The best conserved region is a stretch of 12 residues which are located in a cytoplasmic loop between the second and third transmembrane domains. Some Gram-positive bacteria also encode a soluble diacylglycerol kinase capable of reintroducing DAG into the phospholipid biosynthesis pathway. DAG accumulates in Gram-positive bacteria as a result of the transfer of glycerol-1-phosphate moieties from phosphatidylglycerol to lipotechoic acid.[4]

Mammalian DGK Isoforms

[edit]

Currently, nine members of the DGK family have been cloned and identified. Although all family members have conserved catalytic domains and two cysteine rich domains, they are further classified into five groups according to the presence of additional functional domains and substrate specificity.[5] These are as follows:

  • Type 1 - DGK-α, DGK-β, DGK-γ - contain EF-hand motifs and a recoverin homology domain
  • Type 2 - DGK-δ, DGK-η - contain a pleckstrin homology domain
  • Type 3 - DGK-ε - has specificity for arachidonate-containing DAG
  • Type 4 - DGK-ζ, DGK-ι - contain a MARCKS homology domain, ankyrin repeats, a C-terminal nuclear localisation signal, and a PDZ-binding motif.
  • Type 5 - DGK-θ - contains a third cysteine-rich domain, a pleckstrin homology domain and a proline rich region

Clinical Significance

[edit]

In a phenotypic screen for small molecules that could stimulate interleukin-2 (IL2) secretion from primary T cells in the presence or absence of PD-1 suppression, BMS-684 was found to be able to act as a T cell checkpoint inhibitor. Further optimization led to the compound BMS-496. Using lipid-based photoaffinity probes, DGKα was identified as the primary target of BMS-496. BMS-496 induces translocation of DGKα to the plasma membrane. Further study found that these compounds also inhibit DGKζ and similarly induce translocation of DGKζ to the plasma membrane. Preclinical studies found that this strategy of dual DGKα/ζ inhibition can potentiate the anticancer effects of PD-1 blockade.[6][7]

References

[edit]
  1. ^ Shulga, Yulia V.; Topham, Matthew K.; Epand, Richard M. (2011). "Regulation and Functions of Diacylglycerol Kinases". Chemical Reviews. 111 (10): 6186–6208. doi:10.1021/cr1004106. PMID 21800853.
  2. ^ Mérida I, Avila-Flores A, Merino E (January 2008). "Diacylglycerol kinases: at the hub of cell signalling". The Biochemical Journal. 409 (1): 1–18. doi:10.1042/BJ20071040. PMID 18062770.
  3. ^ Smith RL, O'Toole JF, Maguire ME, Sanders CR (September 1994). "Membrane topology of Escherichia coli diacylglycerol kinase". Journal of Bacteriology. 176 (17): 5459–65. doi:10.1128/jb.176.17.5459-5465.1994. PMC 196734. PMID 8071224.
  4. ^ Miller DJ, Jerga A, Rock CO, White SW (July 2008). "Analysis of the Staphylococcus aureus DgkB structure reveals a common catalytic mechanism for the soluble diacylglycerol kinases". Structure. 16 (7): 1036–46. doi:10.1016/j.str.2008.03.019. PMC 2847398. PMID 18611377.
  5. ^ van Blitterswijk WJ, Houssa B (October 2000). "Properties and functions of diacylglycerol kinases". Cellular Signalling. 12 (9–10): 595–605. doi:10.1016/s0898-6568(00)00113-3. PMID 11080611.
  6. ^ Wichroski, Michael; Benci, Joseph; Liu, Si-Qi; Chupak, Louis; Fang, Jie; Cao, Carolyn; Wang, Cindy; Onorato, Joelle; Qiu, Hongchen; Shan, Yongli; Banas, Dana; Powles, Ryan; Locke, Gregory; Witt, Abigail; Stromko, Caitlyn (2023-10-25). "DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell–mediated antitumor immunity". Science Translational Medicine. 15 (719). doi:10.1126/scitranslmed.adh1892. ISSN 1946-6234. PMID 37878674.
  7. ^ Chupak, Louis; Wichroski, Michael; Zheng, Xiaofan; Ding, Min; Martin, Scott; Allard, Christopher; Shi, Jianliang; Gentles, Robert; Meanwell, Nicholas A.; Fang, Jie; Tenney, Daniel; Tokarski, John; Cao, Carolyn; Wee, Susan (2023-07-13). "Discovery of Potent, Dual-Inhibitors of Diacylglycerol Kinases Alpha and Zeta Guided by Phenotypic Optimization". ACS Medicinal Chemistry Letters. 14 (7): 929–935. doi:10.1021/acsmedchemlett.3c00063. ISSN 1948-5875. PMC 10351048. PMID 37465293.
[edit]